Mixed ASCO 2026 data and pipeline questions weigh on AZN shares
- ASCO 2026 (May 29-June 2) featured AZN presentations including EMERALD-3 positive results for Imfinzi/Imjudo triplet in early liver cancer (improved PFS/survival).
- Recent CARES Phase 3 (announced May 29) missed primary endpoint overall for anselamimab in amyloidosis but showed 62% mortality reduction in kappa subgroup at ASCO.
- Competitor sac-TMT Phase 2 data (65% PFS risk reduction in 1L NSCLC) raises efficacy/biomerker questions for AZN's Datroway (TROP2 ADC); AVANZAR survival data pending H2 2026.
- Conference described as "quiet" for European pharma with AZN/Roche having "work to do" on key assets' commercial futures per analyst reports.
- Lingering May concerns include FDA review extension and prior ODAC rejection (6-3 vote) for camizestrant in breast cancer.
- Stock declined ~2.55% on June 1 despite some positive readouts, as data failed to strongly advance $40B oncology ambition or resolve competitive risks.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.